02 August 2023
02 August 2023
The company's updated 2023 guidance predicts revenues in the $67bn-$70bn range.
The transaction will be concluded in November 2023.
The ten-year US Department of Health contract is for the development, manufacturing scale-up and procurement of Ebanga.
The technology will aid UBC in streamlining workflow through routine step automation, reducing manual work and processing times.
TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently under development to treat skeletal dysplasias.
The announcement follows the recent initiation of a Phase I/IIa solid tumour study, which will recruit up to 117 subjects.
Vepdegestrant was awarded the Innovation Passport designation for treating advanced or metastatic breast cancer.
As government funding for Covid-19 medicine tapers off, companies are returning to normal profits.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
